Company retains an influential clinician for the launch of its innovative software for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Charles H. Adler, MD, PhD, has accepted to serve on neuropacs’ Board of Clinical Advisors.
“Dr. Adler brings much clinical expertise and insight to neuropacs” stated Dr. Martin Handfield, neuropacs’ President and CEO. He added:” Dr. Adler’s research has led to several advances in patient care and is focused on identifying the causes and improving the treatment of Parkinson’s disease, dementia, essential tremor, dystonia and other movement disorders. This includes work with the Arizona Study of Aging and Neurodegenerative Disorders and the Parkinson’s Progression Markers Initiative. These projects are leading to the development of tissue biopsies and other biomarkers to help diagnose Parkinson’s disease. He served as the Secretary-Elect and then Secretary of the International Parkinson and Movement Disorder Society from 2019-2023. He has been awarded several professional recognitions, including the Wayne and Kathryn Preisel Professorship in Neuroscience Research, Mayo Clinic, 2022, and the Movement Disorders Research Award, American Academy of Neurology, 2022”, Handfield concluded.
Dr. Adler commented:” I’m delighted to interface with neuropacs’ Founders and their Management Team, and I believe that neuropacs’ novel diagnostic tool has the potential to change how several neurodegenerative diseases will soon be diagnosed, ultimately enabling earlier interventions, better patient stratification in clinical trials and ultimately improved patient outcomes.”
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.